Biocon's Malaysian arm gets 6 observations from USFDA after inspection

27 Sep 2021 Evaluate

US Food and Drug Administration (USFDA) has issued six observations after the inspection of the manufacturing facility of Biocon’s Malaysian subsidiary Biocon Sdn Bhd. USFDA conducted an on-site pre-approval inspection of the company's Malaysian subsidiary Biocon Sdn Bhd's manufacturing facility for Insulin Aspart between September 13 and September 24, 2021. At the conclusion of the inspection, the agency has issued a Form 483 with a total of 6 observations across Drug Substance, Drug Product and Devices Facilities.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

278.60 7.60 (2.80%)
23-Apr-2024 14:28 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1481.35
Dr. Reddys Lab 5981.75
Cipla 1357.35
Zydus Lifesciences 962.20
Lupin 1584.50
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.